about
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overviewEffects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome.Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.Omalizumab therapy for children and adolescents with severe allergic asthma.Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery.Chronic Hepatitis C Virus Infection and Depression.T-2 toxin immunotoxicity on human B and T lymphoid cell lines.Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis.Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review.CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence.Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients.Determination of molecular marker expression can predict clinical outcome in colon carcinomas.Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome.Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia.Epidemiology of allergic occupational diseases induced by Tetranychus urticae in greenhouse and open-field farmers living in a temperate climate area.Uncommon immune-mediated extrahepatic manifestations of HCV infectionElevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinomaA true splenic cyst producing carbohydrate antigen 19-9 and cancer antigens 50 and 125, but not interleukin 10Serum interleukin-10 levels in patients with advanced gastrointestinal malignanciesPrognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgeryMaintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticariaA subtle case of iron-deficiency anemiaBehavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgeryEffects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary reportChoosing the most appropriate biologic therapy for Crohn's disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions
P50
Q28082212-C5539747-FC58-4BED-B986-761D64A441D6Q35567866-394F75CE-7886-47B3-A3FF-6E0C96A11AF5Q38157936-9F42250D-6BE5-440F-91E3-433E390C7B38Q38574776-ABB983E6-7001-4388-A2A3-AA354D313412Q38656029-3BB14CAE-C9BF-47E7-93C8-86FA1C3289C7Q39423704-D443A425-722E-4E55-90DE-A56910FD2A21Q40440012-B8765215-846C-4772-BA26-F88771F06080Q41146298-7281E287-A859-4D01-82BC-9BBF01D1E2F3Q42367627-6CFAF34C-3446-4FC0-B6A0-67314A5ACE66Q43114039-687DB476-F735-49AA-AF2E-522CB0EC1E77Q45346166-D984C733-6431-454B-B371-A7E3A283517AQ47433453-080A6C1C-6A7A-445D-A637-04892F41FF08Q47680779-0DD9D369-3BAC-47BB-B538-DDC4F1E39FE6Q48179396-9FBAAE1B-E646-4805-9B68-A0B16E0B5F1DQ52976551-251D9D5C-E4DA-4615-BEF7-E6C3B54F9673Q53000708-B35CA84A-1BD6-4F6C-AE9B-CBE0ACCCBDFCQ53881990-C9736BCC-B2F7-4150-8B15-C70C2C574165Q58587420-B93F88D8-1C43-4F6D-B9A0-A6C02E235A32Q62992508-C81A39D7-B6BB-4709-BD76-452F42919D68Q73128799-316C5041-5078-403E-8125-3369FB8454F7Q73202292-385B9295-EBEE-434A-8FA5-8FFC2C2C752CQ81205846-4822D012-9D96-4875-83FD-260CAFE8091FQ82839788-72B19F00-1889-4E98-B05F-BFC348C8E7CAQ84373359-D41D164F-92D8-4F6A-BCEE-04CE7942BCE5Q84940964-087AE218-E0A9-41D7-AE1E-2F53A89E8EACQ88624623-5CB76CFB-E59D-4AC2-A842-B386EB106F38Q91127090-3F4DE021-9C35-4E13-8451-A02E04802C35
P50
description
researcher ORCID ID = 0000-0002-5807-6601
@en
wetenschapper
@nl
name
Ciro Romano
@ast
Ciro Romano
@en
Ciro Romano
@es
Ciro Romano
@nl
type
label
Ciro Romano
@ast
Ciro Romano
@en
Ciro Romano
@es
Ciro Romano
@nl
prefLabel
Ciro Romano
@ast
Ciro Romano
@en
Ciro Romano
@es
Ciro Romano
@nl
P1153
7203070564
P21
P31
P496
0000-0002-5807-6601